Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

What happened

Anteris announced 30-day outcomes for its medium-size DurAVR transcatheter heart valve in a small group of patients with severe aortic stenosis and medium aortic annuli in the EMBARK Study. It reported low pressure gradients, large effective valve openings, no moderate or severe leaks, and no valve-related deaths.

Confirmed

Global impact / market context

These early results could support further evaluation of DurAVR and, if later evidence and regulatory steps are favorable, improve Anteris’s ability to commercialize the valve. Commercial adoption could generate device revenue, while clinical or regulatory setbacks could delay sales and require more development spending.

Analyst inference

The results describe an early clinical snapshot, not proof of lasting benefit or broad hospital demand. If later study findings support the reported valve performance, they could strengthen Anteris’s case for regulatory progress and eventual sales; weaker results could limit those prospects.

Analyst inference

What to watch

1. Look for longer EMBARK Study follow-up to learn whether the reported valve performance and lack of serious complications continue beyond the initial follow-up period. Analyst inference
2. Watch for further study results and regulatory updates, which may clarify whether Anteris can advance the medium-size valve toward broader use and future sales. Analyst inference
3. The article reports no valve-related deaths or moderate or severe leaks in the medium-annulus patient group at the reported follow-up point. Confirmed

Evidence

• globenewswire.com